07 Oct 2026
Transmission of Annual Report for the Year Ended 30-06-2026 Ferozsons Laboratories Limited transmitted its Annual Financial Statements for the year ended June 30, 2026, to the Pakistan Stock Exchange as required. Financials 07 Oct 2026
Notice of Annual General Meeting Ferozsons Laboratories Limited has issued a notice for its 70th Annual General Meeting (AGM) to be held on Wednesday, 28 October 2026, at 12:45 P.M. at Blue Lagoon, Masood Akhter Kiani Road, Rawalpindi and through video link. The agenda includes adopting financial statements, approving a final cash dividend of 55% (Rs. 5.50 per share) for the year ended 30 June 2026, appointing auditors, and ratifying related party transactions. Meetings 06 Oct 2026
Notice of Annual General Meeting prior to publication Ferozsons Laboratories Limited has issued a notice for its 70th Annual General Meeting (AGM) scheduled for October 28, 2026, to consider financial statements, approve a final cash dividend of 5.50 per share (55%), appoint auditors, and vote on related party transactions. Meetings 29 Sep 2026
Financial Results for the Year Ended 2026-06-30 Ferozsons Laboratories Limited announced its annual financial results for the year ended June 30, 2026, reporting a consolidated profit after tax of PKR 1,227.73 million (EPS: PKR 22.51) compared to PKR 921.71 million (EPS: PKR 17.86) in the previous year. On an unconsolidated basis, profit after tax stood at PKR 650.90 million (EPS: PKR 14.97) versus PKR 528.24 million (EPS: PKR 12.15). Financials 22 Sep 2026
Board Meeting Ferozsons Laboratories Limited has announced that a meeting of its Board of Directors will be held on September 29, 2026, to consider the annual financial results for the period ended June 30, 2026, and potential entitlements. A closed period has been declared from September 22, 2026, to September 29, 2026. Meetings 17 Sep 2026
Material Information Ferozons Laboratories Limited has entered into a royalty-free voluntary licensing agreement with Gilead for the manufacture and sale of lenacapavir for HIV prevention in 120 low- and lower-middle-income countries. The agreement covers technology transfer and manufacturing readiness, with the injectable variant to be produced by its JV subsidiary BF Biosciences and the oral variant by Ferozons directly. Material 15 Jul 2026
Appointment of Chairperson and Chief Executive Officer OTHERS 15 Jul 2026
Approval of Annual Budget for FY 2026-27 The Board of Directors of Ferozsons Laboratories Limited has approved the company's annual budget for the fiscal year 2026-27 during their meeting held on July 14, 2026. OTHERS 07 Jul 2026
Board Meeting Other Than Financial Results Ferozsons Laboratories Limited has announced a board meeting scheduled for July 14, 2026, to discuss key governance matters including the election of the Chairman, appointment of the Chief Executive, constitution of board committees, and approval of the annual budget for FY2027. A closed period has been declared from July 7 to July 14, 2026. Meetings 03 Jul 2026
Certified True Copy of Resolution passed by the Shareholders in EOGM of the Company held on July 03, 2026 Ferozsons Laboratories Limited held an Extraordinary General Meeting (EOGM) on July 03, 2026, where shareholders confirmed the minutes of the 69th Annual General Meeting and elected seven directors for a three-year term starting July 07, 2026. OTHERS 24 Jun 2026
Election of Directors OTHERS 19 Jun 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 19 Jun 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 19 Jun 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Mr. Shahid Anwar, a Non-Executive Director of Ferozsons Laboratories Limited, purchased 100 shares of the company at a price of 406.50 per share on June 19, 2026. Insiders 12 Jun 2026
Notice of Extraordinary General Meeting OTHERS 11 Jun 2026
Notice of Extraordinary General Meeting prior to publication OTHERS 02 Jun 2026
Intimation of Passing Away of Mrs. Akhter Khalid Waheed, Chairperson and Director Ferozsons Laboratories Limited has announced the passing of its Chairperson and Director, Mrs. Akhter Khalid Waheed. The company stated that the resulting casual vacancy on the Board of Directors will be filled in accordance with regulatory requirements. Material 30 Apr 2026
Transmission of Quarterly Report for the Period Ended 31-03-2026 Financials 29 Apr 2026
Financial Results for the Quarter Ended 31-03-2026 Financials 22 Apr 2026
Board Meeting Ferozsons Laboratories Limited has scheduled a board meeting for April 29, 2026, to review the quarterly financial results for the period ending March 31, 2026, and to consider any potential dividend or other entitlements. Meetings 
